Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

Related Keywords

United States ,Japan ,Georgia ,Atlanta ,America ,Suresh Ramalingam ,Susan Galbraith ,Astrazeneca ,Winship Cancer Institute Of Emory University ,World Health Organization ,Oncology Research Development At Astrazeneca ,Winship Cancer Institute ,Emory University ,South America ,Oncology Research ,D ,Osimertinib ,Nsclc ,Egfr Mutant Nsclc ,Phase 3 Laura Trial Nct03521154 ,